Targeting CDK4 and CDK6: From Discovery to Therapy.

Area of Science:

• Cell Biology
• Molecular Biology
• Oncology

Background:

• Decades of research elucidated the role of D-type cyclins, cyclin-dependent kinases (CDK4 and CDK6), and p16(INK4) in regulating cell cycle progression.
• The retinoblastoma protein (Rb) pathway is central to mammalian cell entry into the DNA synthetic (S) phase.

Purpose of the Study:

• To review the discovery and characterization of CDK4/6 and their regulators.
• To discuss the translation of CDK4/6 biology into clinical applications for cancer therapy.
• To highlight the development of rational combinatorial therapies targeting CDK4/6.

Main Methods:

• Biochemical and genetic characterization of cell cycle regulators.
• Preclinical investigations into the therapeutic potential of CDK4/6 inhibitors.
• Analysis of clinical trial data for CDK4/6-targeted therapies.

Main Results:

• CDK4/6 inhibitors, especially in combination therapies, show significant promise in cancer treatment.
• FDA approval of palbociclib with letrozole for breast cancer demonstrates clinical success.
• Emerging data support CDK4/6 inhibitors as effective anticancer drug targets.

Conclusions:

• Selective CDK4/6 inhibitors have validated these kinases as viable anticancer drug targets.
• The findings support the development of novel combinatorial strategies for cancer treatment.
• Ongoing clinical trials are exploring CDK4/6 inhibitors in a broader range of cancers.